News Room

For Press Contact
In The News

Integra Connect Launches Advanced Analytics Suite to Help Oncology Practices Improve Cost-Efficiency and Quality of Value-Based Cancer Care

Integra Connect  

Integra Connect Intelligence Unites Disparate Clinical and Financial Data, Enabling Community Oncologists to Predict High-Impact Interventions at Patient and Population Levels

West Palm Beach, FL – Integra Connect, the leading provider of technologies and services for value-based specialty care, today announced the availability of Integra Connect Intelligence, a suite of advanced analytics built specifically for oncology practices increasingly accountable for the cost and quality of cancer care as part of participation in the Oncology Care Model (OCM) and other value-based care programs.

The advanced analytics suite enables oncology practices to unify disparate sources of patient data residing in siloed systems throughout the healthcare ecosystem; apply Integra Connect’s proprietary algorithms to stratify and segment those patients on population and individual levels; and run predictive models via a machine learning engine to anticipate cost and quality outliers requiring personalized treatment plans. Integra Connect Intelligence is fully integrated with the company’s other population health technologies and services, ensuring practices can act on analytical insights via proven interventions to improve quality and cost.

“During the past year, our close collaboration with many of the nation’s pre-eminent oncology practices around the OCM has shed light on the greatest areas of uncertainty they face in successfully managing populations for value-based care,” said Charles Saunders, MD, CEO of Integra Connect.  “It has also highlighted the obstacles presented by the inability to access and make sense of massive amounts patient data distributed across EHRs, claims, labs, pharmacy, and a host of other systems. With Integra Connect Intelligence, we unify and harmonize patient data and identify the highest-impact cost and quality improvement opportunities, all powered by proprietary algorithms and predictive models developed by our data science teams.”

Virginia Cancer Institute (VCI), an independent group of 24 nationally-known oncologists, is an early user of the advanced analytics solution. “Delivering the highest-quality care for our cancer patients within the parameters of the evolving value-based healthcare delivery system requires that we constantly enrich our understanding of quality and cost drivers on a personal level, as well as across our many populations,” said Tom Gallo, Executive Director of VCI. “Integra Connect’s analytics have helped VCI to synthesize massive amounts of complex data in service of a more holistic, actionable view of the quality and efficiency of the value-based care we provide.”

The Integra Connect Intelligence analytics suite sits atop a proprietary Data Transaction and Exchange engine that pulls from a practice’s disparate clinical and financial data sources, regardless of vendor – from EHRs and practice management systems to claims and more – to create a single source of truth about each patient, then stores the data. This feeds a library of turnkey reports and dashboards aligned with clinical and financial priorities set forth by the OCM and other value-based care programs. Intelligence enables analysis at the practice, site, provider, and patient levels across areas including:

  • Quality of Care: Providing oncology practices with near real-time visibility into their performance under MIPS, the OCM or other alternative payment models.
  • Cost and Utilization: Uncovering high-impact cost improvement opportunities, from resource utilization to avoidable or manageable adverse events.
  • Predictive Analytics: Identifying and scoring patients at high, medium or low risk of adverse events – with the ability to drill-down and sort results by patient population subsets, such as risk level, physician, event type, cancer type, and more.
  • Care Bundle Episode Identification: Identifying care bundle-eligible patients (e.g. OCM participants), including those prescribed oral chemotherapies, facilitating follow-up.

Care management performance and network leakage round out the suite, with additional capabilities to be added in the months ahead.

“We are already working on the next generation of population health analytics capabilities to support our customers’ ongoing value-based care success,” continued Saunders. “With our data transaction and exchange engine in place, we will constantly broaden the data inputs – with a focus on genomic and molecular data – while producing insights that help realize the promise of precision medicine through personalized treatment options at the point of care.”

Integra Connect Intelligence will be commercially available to all community oncology practices in the late spring of 2018.

Alyssa Howerton  
240 816 1645 

SOURCE Integra Connect